Cambrex is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance manufacturing capacity. The work, which will convert a previously customer-dedicated manufacturing train, will include an additional production line at 6 m³ scale, resulting in a 25 percent capacity increase at the facility.
Engineering work began and is expected to be completed by November 2020. The work involves modification of an existing 4 reactor configuration and the installation of new holding tanks and a 4 m2 Hastelloy Rosemund filter.
Cambrex's site in Karlskoga employs more than 400 people and features a wide range of flexible manufacturing facilities, including 4 cGMP pilot plants and 5 full-scale commercial production units. In 2019, a new 600 m2 process and analytical development facility was added to the site, along with a 3,000 m2 logistics center.